castanyes blaves

http://www.medadnews.com/News/Index.cfm?articleid=289170

SAN DIEGO--(BUSINESS WIRE)--Nov 8, 2005 - Illumina, Inc. (NASDAQ: ILMN) announced today that it has signed a multi-phase genotyping services agreement to support colorectal cancer researchers funded by Cancer Research UK, the world's leading independent charity dedicated to cancer research. The multi-million dollar agreement extends over several years and includes two major phases. In the first phase of the project, Illumina's service group will conduct dense, whole-genome genotyping (greater than 500,000 single nucleotide polymorphisms, or SNPs, per sample) for at least 4,000 well-classified colorectal patients and controls. In the second phase, Illumina will genotype over 10,000 samples using a custom, multi-sample BeadChip that will enable analysis of 20,000 SNPs per sample. Both phases will use Illumina's Sentrix(R) Arrays and Infinium(TM) Assay with the option to employ related assay methods.

posted by avilella  # 3:53 PM